Views: 0 Author: Site Editor Publish Time: 2025-07-25 Origin: Site
CAS No. 106261-49-8, also known as (R)-9-(2-Phosphonomethoxypropyl)adenine hemifumarate or Tenofovir base, is a critical intermediate in the production of Tenofovir disoproxil fumarate (TDF) and Tenofovir alafenamide (TAF), both of which are cornerstone antiviral drugs used for the treatment of HIV/AIDS and hepatitis B.
This compound falls under the nucleotide reverse transcriptase inhibitor (NRTI) class and is essential in the manufacturing process of generic and branded antiviral medications used worldwide.
Serves as the base compound from which Tenofovir derivatives like TDF and TAF are developed.
Tenofovir-based medications are among the most prescribed antivirals in both high-income and developing nations.
The production process must meet stringent GMP, FDA, and EMA standards due to the compound's therapeutic importance.
Tenofovir is widely distributed through global programs such as PEPFAR, The Global Fund, and WHO initiatives.
Both innovators and generic drug manufacturers rely on a consistent supply of high-purity CAS 106261-49-8 for their production needs.
Location: California, USA
Overview: As the original developer of Tenofovir, Gilead ensures supply of CAS 106261-49-8 through licensed partners worldwide.
Specialty: Originator molecule with strict quality protocols.
Location: Barcelona, Spain
Overview: Offers GMP-compliant production of phosphonate intermediates like Tenofovir base to major generic API makers.
Specialty: Efficient, scalable supply of high-purity antiviral intermediates.
Location: Changzhou City, Jiangsu Province, China
Overview: A specialized producer of antiviral intermediates including CAS 106261-49-8, Eastfine delivers reliable, export-ready materials with global documentation.
Specialty: Cost-effective, high-purity Tenofovir intermediates.
Location: Milan, Italy
Overview: A European leader in nucleoside and nucleotide intermediate production, Olon offers full regulatory compliance and scalable production.
Specialty: EMA- and FDA-audited facilities for antiviral building blocks.
Location: Hyderabad, India
Overview: Provides CDMO services and large-scale production of Tenofovir base, with emphasis on global quality standards.
Specialty: Route optimization and chiral chemistry expertise.
Location: Mumbai, India
Overview: A pioneer in affordable HIV treatment, Cipla produces Tenofovir and its intermediates for global public health programs.
Specialty: WHO-prequalified facilities and reliable international supply.
Location: Bubendorf, Switzerland
Overview: Offers GMP production of Tenofovir-related intermediates with full analytical and regulatory support.
Specialty: Custom synthesis and high containment for phosphonate chemistry.
Location: Maharashtra, India
Overview: Manufactures and exports high-purity phosphonate intermediates used in antiviral API production.
Specialty: Robust quality systems and large-scale manufacturing capabilities.
Location: Montreal, Canada
Overview: A well-established manufacturer of high-purity antiviral intermediates, including Tenofovir base, for regulated markets.
Specialty: North American quality and regulatory transparency.
Location: Gujarat, India
Overview: Supplies a wide range of pharmaceutical intermediates, including phosphorous-containing compounds like CAS 106261-49-8.
Specialty: Reliable intermediate production and supply chain support.
The scale-up of antiviral treatments in Africa, Asia, and Latin America has led to sustained demand for Tenofovir intermediates.
Generic manufacturers are under pressure to reduce costs, driving interest in high-quality yet competitively priced intermediates.
Stricter ICH guidelines and compliance expectations are leading to more investments in GMP and impurity control.
Manufacturers are innovating cleaner, safer processes for producing phosphonic acid derivatives.
Many drug developers now outsource intermediate production to CDMOs with proven expertise in nucleotide chemistry.
CAS No. 106261-49-8 is an indispensable intermediate for the production of Tenofovir-based therapies, which remain among the most important treatments in the global fight against HIV/AIDS and hepatitis B. With leading manufacturers like Eastfine, Farmhispania, Sai Life Sciences, and Olon, the industry is well-equipped to meet global demand through compliant, efficient, and scalable production.
Whether for branded pharmaceuticals or high-quality generics, this compound will remain a foundational element in public health initiatives for years to come.
简体中文
